Value of 18F-FDG PET/CT in patients with hepatic metastatic carcinoma of unknown primary.

Abstract

PURPOSE:

This retrospective study aimed to investigate the clinical value of -deoxy-2-(F)-fluorodeoxyglucose positron emission tomography/computed tomography (F-FDG PET/CT) in detecting primary lesions of hepatic metastases.

METHODS:

A total of 124 patients with hepatic metastatic carcinoma of unknown primary underwent whole body F-FDG PET/CT imaging. According to the final diagnoses for both primary sites and hepatic metastases that were confirmed either histopathologically or by clinical follow up, all patients were divided into 4 groups: a true positive group (TP, 95 cases), a false positive group (FP, 9), a true negative group (TN, 8) and a false negative group (FN, 12).

RESULTS:

The TP rate of primary lesions, detected by F-FDG PET/CT, was 76.61%, the FP rate 7.26%, the TN rate 6.45% and the FN rate 9.68%. The sensitivity, specificity, positive predictive value, negative predictive value and accuracy of F-FDG PET/CT in the detection of primary tumors were 88.78%, 52.94%, 91.35%, 40%, and 83.06%, respectively. Accurate diagnosis groups (TP, TN) showed a significantly higher SUVmax (standard uptake maximum value) level than that in error diagnosis groups (FP, FN). The SUVmax between hepatic metastases and primary lesions had a positive correlation. The primary tumor sites of hepatic metastases were mainly located in the gastrointestinal organs and the lungs.

CONCLUSIONS:

Whole body F-FDG PET/CT imaging was sensitive for detecting primary sites/lesions with hepatic metastatases of unknown primary, especially when the SUVmax of hepatic metastases were greater than 4.7.

• Authors: Yuekai Li, Fengcai Li, Xin Li, Lili Qu, Jiankui Han
• Journal: Medicine (Medicine (Baltimore)) Vol. 99 Issue 50 Pg. e23210 (Dec 11 2020) ISSN: 1536-5964 [Electronic] United States
• PMID: 33327238 (Publication Type: Journal Article)

Chemical References

• Radiopharmaceuticals
• Fluorodeoxyglucose F18

Topics

• Adult
• Aged
• Aged, 80 and over
• Carcinoma (diagnostic imaging)
• Case-Control Studies
• Female
• Fluorodeoxyglucose F18 (administration & dosage, metabolism)
• Humans
• Liver Neoplasms (pathology, secondary)
• Male
• Middle Aged
• Neoplasm Metastasis (diagnostic imaging, pathology)
• Neoplasms, Unknown Primary (pathology)
• Positron Emission Tomography Computed Tomography (methods)
• Predictive Value of Tests
• Radiopharmaceuticals (administration & dosage, metabolism)
• Retrospective Studies
• Sensitivity and Specificity